Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
Chongqing Precision Biotech Co., Ltd
Modality
Cell therapy
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04272151CT.gov Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma | — | Unknown | — | — | — |
NCT04271644CT.gov BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Plasma Cell Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Bcma Car-T Cells (this asset) | Chongqing Precision Biotech Co., Ltd | P1/2 | CCC · 48 |
| Lenalidomide | Hellenic Society of Hematology | P3 | BBB |
| Dexasone | Hellenic Society of Hematology | P3 | BBB |
| Cyclophosphamide | Affiliated Hospital to Academy of Military Medical Sciences | P3 | BB |
| Fludarabine | Affiliated Hospital to Academy of Military Medical Sciences | P3 | BB |
| Nivestim | Hellenic Society of Hematology | P3 | BB |
| Tacrolimus | Dartmouth-Hitchcock Medical Center | P3 | BB |
| Busulfanum | Baylor College of Medicine | P2 | B |
| Melphalan | Roswell Park Cancer Institute | P2 | B |
+41 more in the Plasma Cell Neoplasm cohort
Other indications for Bcma Car-T Cells
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Plasma Cell Myeloma | — | P2 | B · 58 |
| Neoplasm | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Bcma Car-T Cells in Plasma Cell Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/bcma-car-t-cells-plasma-cell-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →